Taken together, this indicates that PTCL-S1 can be useful as a TP63-rearranged ALK-negative ALCL in vitro model to investigate new treatment candidates as well as to better understand the genetic and molecular features of ALK-negative TP63-rearranged ALCL. This evidence concerns the gene ALK and anaplastic large cell lymphoma.